. It is expressed in the Gag poly protein, which is specifically cleaved by the viral protease in immature virions to form matrix, capsid, NCp7 and p6. NCp7 contains two zinc fingers with the strictly conserved motif C-X 2 -C-X 4 -H-X 4 -C that are flanked by residues highly conserved among viral clades [6] [7] [8] . Intact zinc fingers are critical for NCp7 function, Gag processing and infection [8] [9] [10] [11] . Electrophilic molecules that have been developed to eject co ordinated zinc from NCp7 show antiviral activity 4, 5 , yet their toxicity or lack of specificity has hampered their development into drugs 12 . We have discovered that S-acyl-2-mercaptobenzamide thioesters (SAMTs) specifically eject zinc from the C-terminal zinc finger of NCp7 in vitro 13, 14 , resulting in irreversible unfolding of the NCp7 structure. SAMTs inhibit viral activity in cell-based assays, with a half-maximal effective concentration (EC 50 ) of <50 nM for inhibition of cell-to-cell HIV-1 transmission 14 . Although SAMTs react with selected cellular zinc finger motifs in vitro 15 , they show low cytotoxicity in cell culture and animal models 16, 17 . In vitro experiments using NCp7 32-55 , which contains the C-terminal zinc finger, revealed that reversible acyl transfer between the SAMT and sulfur side chain of Cys36 is rapidly followed by irreversible intramolecular transfer of the acyl group to one of several proximal lysine residues 7 . As treatment of HIV-infected cells with NCp7 zinc ejectors results in accumulation of aggregated, unprocessed Gag polyprotein 4, 5 , we investigated whether SAMT treatment would elicit a similar effect. For these experiments, we used SAMT-247 (1, Fig. 1a) , a simple SAMT with good antiviral activity (EC 50 = 0.6-5.7 μM) and low cellular toxicity (TC 50 > 100 μM) in cultured and primary cells (Fig. 1a and Supplementary Table 1) . Analysis of the virions from chronically HIV-infected H9 cells treated with SAMT-247 as described in the Supplementary Methods demonstrated that treatment did result in the decrease of NCp7, the appearance of its precursor Gag (55 kDa) and the accumulation of high-molecular weight proteins containing NCp7 (Supplementary Fig. 1a,b) .
Immunoblotting with other Gag antisera demonstrated that the high-molecular weight proteins were composed of NCp7 and/or Gag (Supplementary Fig. 1c ). HPLC purification of Gag from SAMT-treated virions indicated that ~20% of total Gag was modified by SAMT-247. The presence of unprocessed Gag polyprotein in the virions from SAMT-treated cells is consistent with other NCp7 inhibitors 9, 18 and demonstrates that proper zinc coordination is important for Gag processing. Notably, there was no evidence of partial Gag processing, suggesting that Gag was either processed fully or not at all. Exogenous HIV protease was unable to digest Gag in SAMT-treated virions (Supplementary Fig. 1b) , suggesting that treated Gag exists in a nonfunctional complex, likely because of cysteine cross-linking, which renders the virus noninfectious.
We hypothesized that SAMT-247 would covalently modify the NCp7 region of Gag inside cells as observed for NCp7 32-55 in vitro 7 .
Chronically infected H9 cells were treated overnight with SAMT-247 that was 14 C labeled on the methyl carbon of the acetyl group (marked with an asterisk in Fig. 1a) . Analysis of the virions by reducing gel electrophoresis showed specific radiolabeling of Gag (Fig. 1b) , demonstrating that SAMT-247 promotes covalent acetylation of Gag intracellularly. Immunoblot analysis of a parallel experiment confirmed that the protein modified was Gag (Fig. 1c) . Mass spectrometry analysis of Gag purified from chronically infected H9 cells treated with unlabeled SAMT-247 showed modification of Gag residues 402-422 (NCp7 residues 22-42, Supplementary Fig. 2a) . Following reduction and alkylation of the cysteine residues, the acetylation was still observed, indicating that modification occurred on a lysine residue. Tandem mass spectrometry identified the sites as Lys413 and Lys418 ( Supplementary Fig. 2b ), corresponding to Lys33 and Lys38 of NCp7, recapitulating our in vitro results
.
After SAMT reaction with NCp7, a thiol (mercaptobenzamide thiol, MT-1, 2) is generated. Unexpectedly, we found that MT-1 has antiviral activity similar to that of SAMT-247 (Fig. 1a) even though it is inactive in vitro 13 . We hypothesized that MT-1 was activated upon entering cells to form a reactive compound, possibly through acetyl transfer from acetyl-CoA to form SAMT-247. Indeed, incubating MT-1 with acetyl-CoA in vitro resulted in time-dependent formation of SAMT-247 (Supplementary Fig. 3a ) and metal ejection from NCp7 (ref. 13 ). To determine whether this reaction occurred intracellularly, chronically infected H9 cells were treated with and SAMT-247 or MT-1. Analysis of the virions produced by reducing gel electrophoresis demonstrated that treatment with both MT-1 and SAMT-247 resulted in radiolabeling of Gag, just as was observed for treatment with 14 C-SAMT-247 (Fig. 1d) . Likewise, treatment of HIV-infected H9 cells with SAMT-247 or MT-1 in the presence of 2-14 C-pyruvate, which is converted to 14 C-acetyl-CoA by pyruvate dehydrogenase, resulted in radiolabeling of Gag (Supplementary Fig. 3b) . Virions from cells treated with MT-1 also showed similar accumulation of aggregated protein and inhibition of Gag processing as cells treated with SAMT-247 (Fig. 1e,f and  Supplementary Fig. 3c ). The antiviral activity observed for MT-1 was specific for this molecule, as a slightly different thiol (MT-2, 3) did not radiolabel Gag in the presence of 14 C-acetate or 14 C-pyruvate ( Fig. 1d and Supplementary Fig. 3b) . Furthermore, MT-2 showed no antiviral activity, nor did a third thiol, MT-3 (4), containing a methyl ester group in place of the terminal amide (Fig. 1a) . Virions from cells treated with MT-2 or MT-3 showed only background levels of protein aggregation and did not appreciably affect Gag processing (Fig. 1e,f and Supplementary Fig. 3c ).
To further demonstrate the intracellular acetylation of MT-1, we designed a prodrug derivative in which a para-hydroxybenzyl ester was used to mask the sulfur atom (mercaptobenzamide thioether, MTE-1, 5, Fig. 2a) . Inside the cell, the oxygen ester of MTE-1 can be cleaved by esterases to yield an intermediate that breaks down via 1,4-elimination 19 , releasing MT-1 for acetylation to form SAMT-247. As expected, MTE-1 did not react with cell-free NCp7 32-55 , but in cytoprotection assays using cultured and primary cells, it had antiviral activity similar to that of SAMT-247 (Fig. 2b) . A non cleavable control compound (MTE-2, 6) showed significantly reduced activity in all cell types (Fig. 2b) . As observed for MT-1 and SAMT-247, treatment of HIV-infected H9 cells with MTE-1 resulted in Gag aggregation and defects in its processing, whereas treatment with the noncleavable MTE-2 had no effect ( Fig. 2c and Supplementary  Fig. 4a) . Moreover, virions from cells treated with MTE-1 and 14 Cpyruvate showed radiolabeling of Gag similar to MT-1 and SAMT-247 (Supplementary Fig. 4b) . Thus, the effects of MTE-1 treatment were similar to those of the SAMTs, confirming our hypothetical mechanism of action that the thiol produced by reaction with NCp7 can be recycled intracellularly to form an active thioester.
To investigate the importance of the recycling mechanism for SAMT activity, we next tested an activated oxygen ester compound that was not reacetylated following reaction with NCp7 in vitro (Supplementary Fig. 5a, ester-7, 7) . In vitro, ester-7 ejected co ordinated metal from NCp7 32-55 and covalently modified it like SAMT-247 (Supplementary Fig. 5b ). However, it did not inhibit HIV replication in cell-based assays. Furthermore, treatment of HIV-infected H9 cells with ester-7 did not induce protein aggregation or affect Gag processing (Supplementary Fig. 5c,d) . Thus, the lack of cellular activity of ester-7 shows that viral inhibition is lost when reacetylation cannot occur, demonstrating the importance of the recycling mechanism for SAMT antiviral activity.
The results presented here support a model for SAMT inhibition of HIV in which SAMT reaction with NCp7 generates a thiol product that is acetylated by an intracellular mechanism that relies on acetyl-CoA (Fig. 2d) . This reaction regenerates a thioester that can react with additional Gag proteins in a repeating cycle. Acyl transfer from the SAMT to the protein leads to loss of zinc coordination, protein aggregation and inhibition of Gag processing. Even small changes in Gag processing severely decrease HIV-1 infectivity 20, 21 . For example, a 30% block in processing results in a three-log decrease in viral replication 20 . Thus, rather than a simple 1:1 inhibitor/target inactivation model, a single molecule of SAMT could potentially inactivate numerous NCp7 zinc fingers in Gag or free NCp7, a unique mechanism for a small-molecule inhibitor of HIV.
Despite extensive efforts, viral resistance to NCp7 inhibitors has not been observed in treated cells 22 , likely because of the absolute and unvarying requirement for cysteines and surrounding residues in the zinc finger motif. Because MT-1 relies on cellular pathways for activation, HIV-1 resistance via a host cellular mechanism could be difficult to generate as there is no selection pressure for the cell to mutate to accommodate the virus. Furthermore, mutation or downregulation of proteins in the acetyl-CoA and pyruvate pathways is deleterious and associated with disease states 23, 24 . This SAMT-cell partnership mechanism opens new avenues for development of inhibitors of HIV NCp7 and suggests ways to inhibit other diseaserelated proteins containing zinc fingers. 
